SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

ERAS

Erasca, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor upcoming Phase 1 data readouts for ERAS-0015 (H1 2026) and ERAS-4001 (H2 2026) as key catalysts. The expanded China rights and strong IP protection enhance long-term optionality, but near-term valuation remains dependent on clinical execution.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.62
T+0 close · Mar 12, 2026 · via day close
Latest settled
−5.51%
T+60 · $12.87
Vs SPY
−17.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $13.62entry
  2. T+1 · 8mo ago −0.81%α −1.83% · $13.51
  3. T+5 · 8mo ago +7.20%α +9.31% · $14.60
  4. T+20 · 7mo ago +19.75%α +16.16% · $16.31
  5. T+60 · 5mo ago −5.51%α −17.12% · $12.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash position bolstered by a $259 million financing in January 2026. The company emphasized early clinical progress in its RAS-targeting pipeline, including partial responses for ERAS-0015 across multiple tumor types, and expanded its licensing rights globally. Phase 1 data for ERAS-0015 and ERAS-4001 are expected in H1 and H2 2026, respectively.

Key Financial Metrics

EPS
$-0.10
Deal Value
$258.8M

Key Facts

  • Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year prior.
  • Completed upsized public offering in January 2026, raising $258.8 million in gross proceeds, bringing pro forma cash to $434 million.
  • Cash expected to fund operations into H2 2028.
  • Net loss decreased to $29.1 million in Q4 2025 from $32.2 million in Q4 2024; full-year net loss improved to $124.5 million from $161.7 million in 2024.
  • R&D expenses declined to $92.9 million in 2025 from $115.4 million in 2024.
  • Promising early clinical activity for ERAS-0015, including confirmed partial responses in multiple RAS-mutant tumors with favorable safety and pharmacokinetics.
  • Expanded ERAS-0015 licensing agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, securing worldwide rights.
  • U.S. composition-of-matter patents issued for ERAS-0015 (until Sept 2043) and ERAS-4001 (until June 2043).
  • Phase 1 monotherapy data for ERAS-0015 expected in H1 2026; ERAS-4001 data expected in H2 2026.

Financial Impact

Reduced R&D and G&A expenses contributed to a $37.1 million improvement in net loss year-over-year; $258.8 million financing significantly strengthens near-term financial runway.

cashnet_lossr_and_d_expensedilution

Risk Factors

  • Early clinical data are preliminary and may not translate into confirmed responses or regulatory approval.
  • Despite improved cash position, the company remains pre-revenue with significant future funding needs dependent on clinical progress.
  • Forward-looking statements about timelines and financial runway are subject to delays and higher-than-expected costs.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255076

Track record

26 reports on ERAS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026